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Abstract
Background:  An A54T polymorphism at the fatty acid binding protein 2 (FABP2) locus was found
to  be  associated  with  insulin  resistance  in  non-diabetic  Pima  Indians.  To  see  whether  this
association is present in other populations, we performed a cross sectional study to examine the
role of this polymorphism on insulin resistance in 55 healthy and normotensive Caucasian subjects
with normal glucose tolerance. Insulin sensitivity (%S) and beta cell function (%B) were assessed
using the Homeostasis Model Assessment (HOMA). Their genotypes were determined using a
polymerase  chain  reaction-restriction  fragment  length  polymorphism  assay.  The  relationship
between the genotypes and the phenotypes was examined.
Results:  After genotyping, we identified 24 AA, 27 AT and 4 TT subjects. The TT subjects were
combined with the AT subjects during the analysis due to its small sample size. No differences were
noted in gender distribution, clinical features, and fasting lipid profile between the two genotypic
groups (AA vs. AT/TT). The AT/TT group had a higher fasting plasma insulin concentration and a
lower %S than the AA group (p = 0.0444 and p = 0.0461, respectively). However, no differences
were  noted  in  plasma  glucose  concentrations  and  %B.  Univariate  analysis  revealed  that  this
polymorphism  explained  7.3%  of  the  variation  in  %S.  Multivariate  analysis  revealed  that  the
polymorphism was an independent determinant for %S (p = 0.0434) and with body mass index
accounted for 28.7% of the variation in %S. In contrast, this polymorphism had no impact on %B.
Conclusions:  The A54T polymorphism at the FABP2 locus is a risk factor for insulin resistance
in a Caucasian population.
Introduction
The Pima Indians have a very high prevalence for type 2
diabetes mellitus (or non-insulin-dependent diabetes
mellitus, NIDDM) with evidence of strong familial aggre-
gation [1]. In this population, insulin resistance is a ma-
jor risk factor for the development of the disease [2], and
maximal insulin action (i.e. glucose disposal rate at phar-
macological insulin levels) was found to be determined
by a co-dominantly inherited autosomal gene [3]. Initial-
ly, Bogardus and colleagues observed an association and
linkage between insulin resistance and red cell antigens
on chromosome 4q [4]. After the analysis of 128 sib-pairs
using quantitative trait sib-pair analysis, they observed a
significant linkage between maximal insulin action and
the intestinal fatty acid-binding protein 2 (FABP2) gene
and the annexin V (ANX5) gene on chromosome 4q [5].
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It is well recognized that fatty acid metabolism is linked
to insulin resistance [6,7]. Intestinal FABP2 contains a
single ligand binding site that displays a high affinity for
fatty acid [8]. Because it is a candidate gene at this locus,
a search for a mutation was initiated and an Alanine
(GCT) to Threonine (ACT) polymorphism at codon 54
was identified in Pima Indians [9]. The associations be-
tween this polymorphism and fasting insulin concentra-
tion, fasting fat oxidation, and glucose uptake during a
hyperinsulinemic euglycemic clamp were identified in
137 non-diabetic Pima Indians [9].
Because NIDDM is a genetic disorder [10] and results
from an imbalance between insulin sensitivity and beta
cell function, we hypothesized that the A54T polymor-
phism of the FABP2 gene plays a role in the pathogenesis
of insulin resistance, which is one of the key determi-
nants for the development of NIDDM [2]. Since insulin
sensitivity is affected by hypertension [11,12] and abnor-
mal glucose tolerance [2], we examined the relationship
of this polymorphism with insulin sensitivity in 55
healthy and normotensive Caucasians with normal glu-
cose tolerance.
Results
The clinical features of the studied subjects were shown
in Table 1. Using the PCR-RFLP assay, we identified 24
AA, 27 AT, and 4 TT subjects. In this Caucasian popula-
tion, the allele frequency was 68% for the A allele and
32% for the T allele. The distribution of genotypes was in
compliance with the Hardy-Weinberg equilibrium (p =
0.8321).
Since there were only 4 TT subjects, they were pooled
with the AT subjects during the analysis. There were no
differences in clinical features between the two genotypic
groups (AA vs. AT/TT) as shown in Table 2. Although the
AT/TT subjects had a higher fasting plasma insulin con-
centration than the AA subjects (p = 0.0444), no differ-
ences were noted in fasting plasma glucose
concentrations and postchallenged plasma glucose and
insulin concentrations. We estimated insulin sensitivity
(%S) and beta cell function (%B) using the average of the
three fasting plasma glucose and insulin concentrations.
While no difference was noted in %B, the AT/TT subjects
were more insulin resistant (a lower %S) than the AA
subjects (p = 0.0461).
Since a higher body mass index had been reported to be
associated with this polymorphism [13], we were con-
cerned that the observed differences could be the result
of other confounding covariates. A multivariate analysis
was performed to examine the influence of this polymor-
phism and other covariates (Table 3). This polymor-
phism and body mass index explained 28.7% of the
variation in %S and this polymorphism was an inde-
pendent determinant of %S (p = 0.0434). However, this
polymorphism had no impact on %B. Age, gender and
waist hip ratio accounted for 19.5% of the variation in
%B.
Table 1: Clinical features of the studied subjects
Mean* (n) Std. Dev. Minimum Maximum
N5 5
Gender F/M 29/26
Age year 28 6 20 39
Body mass index kg/m2 24.52 3.87 17.58 34.26
Waist-hip ratio cm/cm 0.81 0.09 0.65 1.03
Systolic blood pressure mmHg 114 10 94 137
Diastolic blood pressure mmHg 68 7 55 83
Oral glucose tolerance test
Fasting plasma glucose mM 4.72 0.35 3.88 5.55
Plasma glucose at 30 minutes mM 7.44 1.27 5.49 9.66
Plasma glucose at 60 minutes mM 7.14 1.44 4.44 10.20
Plasma glucose at 90 minutes mM 6.30 1.29 3.62 9.02
Plasma glucose at 120 minutes mM 5.98 1.06 2.94 7.60
* arithmetic meansBMC Genetics (2001) 2:7 http://www.biomedcentral.com/1471-2156/2/7
Discussions
In this study, we found that the A54T polymorphism of
the FABP2 was associated with insulin resistance and ac-
counted for 7.3% of the variation in %S. Multivariate
analysis confirmed that this polymorphism was an inde-
pendent risk factor for insulin resistance. In contrast,
this polymorphism had no impact on %B. Our observa-
tions confirm that the A54T polymorphism of the FABP2
affects insulin sensitivity, which was previously reported
in Pima Indian and Japanese populations [9,14].
The FABP2 locus has been studied extensively. MNS red
cell antigens, one of the few genetic markers available at
that time, were initially found to be linked to insulin re-
sistance in 86 non-diabetic Pima Indians from 31 nuclear
families using a sib-pair analysis and they were also as-
sociated with insulin resistance in 132 non-diabetic Pima
Indians [4]. With additional families and additional ge-
netic markers, a significant linkage was identified be-
tween the FABP2 and ANX5 loci on chromosome 4q with
insulin resistance in 123 non-diabetic subjects from 46
nuclear families [5]. Furthermore, the linkage of the
FABP2 locus with insulin resistance (2-hour postchal-
lenged insulin concentration) was also found in a Mexi-
can-American population, which is genetically related to
the Pima Indians [15]. However, sib-pair analysis failed
to detect any linkage of the FABP2 locus or the A54T pol-
ymorphism with diabetes related phenotypes in other
ethnic groups [16,17] as shown in Table 4A. Further-
more, no linkage was found between the FABP2 locus
(Table 4B) and diabetes [18,19], lipodystrophic diabetes
[20], or obesity [17]. As shown in Table 4C, the popula-
tion association studies of the FABP2 locus with diabe-
tes/impaired glucose tolerance were negative in UK,
Finnish, and Welsh [21] and Japanese populations [22].
Subsequently, the A54T polymorphism was identified
and was found to be associated with increased fatty acid
binding protein, increased fat oxidation and increased
insulin resistance in the Pima Indians [9]. The popula-
tion association studies of the A54T polymorphism with
NIDDM [9,23–25], coronary artery disease [26,27],
obesity [24], and hypertension [24] were also essentially
negative. Positive associations were mostly observed in
quantitative association studies as shown in Table 4D. In
addition to the original positive association between the
A54T polymorphism and fasting plasma insulin concen-
tration, fasting fat oxidation and glucose uptake in non-
diabetic Pima Indians [9], positive association was also
found with obesity [13,14], 2-hour post-challenged insu-
lin concentration [14], and various lipid metabolism
[13,28–30]. In the present study, we also demonstrated
a positive quantitative association between this polymor-
phism and %S. However, numerous negative studies
were also noted [23,24,29,31–33].
Table 2: Clinical features and glycemic parameters by the FABP2 genotypes
AA AT/TT
Mean (n) (95% CI) Mean (n) (95% CI)
N2 4 3 1
Gender F/M 15/9 14/17
Age year 28 (26,31) 27 (25,29)
Body mass index1 kg/m2 23.99 (22.52,25.56) 24.42 (23.03,25.90)
Waist-hip ratio1 cm/cm 0.80 (0.76, 0.84) 0.80 (0.77, 0.83)
Systolic blood pressure mmHg 112 (109,116) 116 (112,120)
Diastolic blood pressure mmHg 68 (65,71) 68 (65,70)
Triglycerides mg/dL 89 (66,110) 73 (57,89)
Total cholesterol mg/dL 166 (152,180) 152 (141,163)
HDL cholesterol mg/dL 50 (45,54) 48 (43,54)
LDL cholesterol mg/dL 98 (85,111) 89 (79,99)
Oral glucose tolerance test
Fasting plasma glucose mM 4.68 (4.53, 4.83) 4.75 (4.62,4.89)
Fasting plasma insulin1,2 pM 55 (48,63) 65 (59,72)
%B1 139 (118,163) 150 (132,171)
%S1,3 0.63 (0.54, 0.73) 0.52 (0.47, 0.58)
1 geometric means; 2 p = 0.0444; 3 p = 0.0461.BMC Genetics (2001) 2:7 http://www.biomedcentral.com/1471-2156/2/7
Clearly there is substantial controversy surrounding this
locus and the A54T polymorphism in the pathogenesis of
insulin resistance and T2DM as described above. Disa-
greement also occurred in the original Pima Indian
study. Although significant linkages were identified at
the FABP2 locus with fasting insulin concentration (p =
0.0004) and with glucose uptake (p = 0.0008) in the
Pima Indians [5], the differences regarding the A54T
polymorphism with fasting insulin concentrations (p <
0.04) and glucose uptake (p < 0.04) were only marginal-
ly significant in the same population [9]. The significant
linkage in the original sib-pair study [5] could be the
combined results of a highly polymorphic marker of the
FABP2 locus (5 alleles vs. 2 alleles for the A54T polymor-
phism) and less intrafamilial difference in insulin sensi-
tivity as the result of familial clustering of insulin
sensitivity. In contrast, the marginal difference reflected
a very modest influence on insulin sensitivity of the A54T
polymorphism in the Pima Indian population, which is
consistent with our observation that this polymorphism
only accounted for 7.3% of the variation in %S in this
Caucasian population. Furthermore, since 1) insulin re-
sistance is neither necessary nor sufficient for the devel-
opment of T2DM, 2) this polymorphism has only a very
modest influence on insulin sensitivity, and 3) beta cell
dysfunction, on which this polymorphism has no influ-
ence in the present study, plays a key role in the develop-
ment of overt diabetes [2], the population association
studies and linkage studies are not able to detect the in-
teraction between this polymorphism and the diabetes
phenotype. In contrast, quantitative studies of diabetes-
related phenotypes become more rewarding in detecting
a polymorphism of a very modest effect as shown in Ta-
ble 4D. The negative quantitative studies could be the re-
sult of other confounding factors, such as the inclusion of
diabetic, impaired glucose tolerant or hypertensive sub-
jects in the study. Therefore, we only enrolled glucose
tolerant and normotensive subjects in the present study
for the reasons described previously.
The most convincing evidence that supports the A54T
polymorphism as a causal mutation is from a functional
study of mutated FABP2 [9]. FABP2 plays a role in the
absorption and intracellular transportation of dietary
long-chain fatty acids [8]. Thr54-containing FABP2 has
a twofold greater affinity for long-chain fatty acids than
the Ala54-containing FABP2 [9]. As predicted by the
proposed [6,7] and subsequently proven [34] "Randle's
cycle", an increased concentration of fatty acid inhibits
glucose uptake in muscle and results in insulin resist-
ance. Furthermore, two interventional studies showed
that this A54T polymorphism affected lipid metabolism
during interventions [35,36], as shown in Table 4E.
In summary, we examined the role of the A54T polymor-
phism in the pathogenesis of insulin resistance in 55 glu-
cose tolerant and normotensive healthy Caucasians. We
found that this polymorphism had an independent, but
very modest influence (7.3%) on insulin sensitivity (%S),
which was assessed by the HOMA. However, it had no
impact on beta cell function (%B). To our knowledge,
this is the very first report of a positive association be-
tween this polymorphism and insulin sensitivity in a
Caucasian population.
Table 3: Multivariate analysis
Dependent 
Variable
Covariate 
Entered
Covariate 
Removed
r2 P
%S 0.287
Body mass index 0.0002
FABP2 
polymorphism
0.0434
Waist-hip ratio 0.1045
Gender 0.5313
Systolic blood 
pressure
0.8157
Age 0.8560
Diastolic blood 
pressure
0.8909
%B 0.195
Age 0.0109
Gender 0.0169
Waist-hip ratio 0.0671
Systolic blood 
pressure
0.2636
Body mass index 0.2684
FABP2 
polymorphism
0.3215
Diastolic blood 
pressure
0.3371BMC Genetics (2001) 2:7 http://www.biomedcentral.com/1471-2156/2/7
Table 4: Published studies of FABP2 and A54T
Subjects/description Genetic marker Result* Phenotype Ref
A. Sib-pair study
Non-diabetic Pima Indians [4]
MNS red cell antigen + maximal insulin-stimulated glucose uptake
+ insulin action index
-fasting insulin
Non-diabetic Pima Indians [5]
ANX5 + maximal insulin-stimulated glucose uptake
FABP2 + maximal insulin-stimulated glucose uptake
+ fasting insulin
Non-diabetic Mexican Americans [15]
FABP2 + 2-h post challenge insulin levels
Pondicherian Tamil Indians [16]
A54T -diabetes, body mass index,
-waist/hip ratio, insulinemia
-glycemia, triglyceride, total cholesterol
French families with morbid obesity [17]
FABP2 -body mass index, adult life body with gain
fasting leptin, insulin, glycerol, free fatty acid
B. Linkage study
Mexican American diabetic pedigrees [18]
FABP2 -diabetes
French diabetic pedigrees [19]
FABP2 -diabetes
Pedigrees with lipodystrophic diabetes [20]
FABP2 -lipodystrophic diabetes
French families with morbid obesity [17]
FABP2 -obesity
C. Population association study
UK, Finnish and Welsh population [21]
FABP2 -diabetes/impaired glucose tolerance
Pima Indian population [9]
A54T -diabetes
Japanese population [22]
FABP2 -diabetes/impaired glucose tolerance
Aboriginal Canadians population [28]
A54T -diabetes
Canadian Inuit population [26]
A54T -coronary artery disease
Diabetic and nondiabetic Finnish population [27]
A54T -coronary artery disease
Japanese population [23]
A54T -diabetes
Japanese population [24]
A54T -diabetes, obesity, hypertension
African Americans population [25]
A54T -diabetes
D. Quantitative association study
Non-diabetic Pima Indians [9]
A54T + fasting insulin, fasting fat oxidation
+ glucose uptakeBMC Genetics (2001) 2:7 http://www.biomedcentral.com/1471-2156/2/7
Subjects and Methods
Subjects
Through the advertisement in the campus newspaper of
this institution, healthy subjects without a prior history
of diabetes and hypertension were invited to participate
in the study. None of the participants were receiving
medical treatment on a regular basis. Subjects were in-
structed to fast for at least 14 hours before the study visit.
On the morning of the visit, subjects were admitted to the
General Clinical Research Center of this institution as
outpatients. An indwelling angiocatheter was inserted
into an antecubital vein. All subjects had fasting blood
samples drawn at -15, -10, and -5 minutes. A blood sam-
ple for the fasting lipid profile was obtained at -15 min-
utes. Fasting plasma glucose and insulin concentrations
were calculated as the average of the three fasting sam-
ples. After an oral administration of 75-gm glucose,
postchallenged blood samples were drawn at 30, 60, 90,
and 120 minutes for glucose and insulin measurements.
A total of 55 Caucasian subjects were enrolled in the
study. They were glucose tolerant (fasting plasma glu-
cose < 6.1 mM, interval plasma glucose < 11.1 mM, and 2-
hour plasma glucose < 7.8 mM), and normotensive
(systolic blood pressure < 140 mmHg and diastolic blood
pressure < 90 mmHg). Plasma glucose and insulin con-
centrations were assayed as described previously [37].
Insulin sensitivity (%S) and beta-cell function (%B) were
estimated based on the Homeostasis Model Assessment
(HOMA) as described elsewhere [38,39]. They were cal-
culated from the average of three fasting plasma glucose
and insulin concentrations (mM and mU/L, respective-
ly) using the following formulae: %S = 22.5 / (insulin x
Aboriginal Canadians [13]
A54T + body mass index, percent body fat
+ fasting plasma triglyceride
Finnish non-diabetic and diabetic subjects [31]
A54T -insulin sensitivity
Obese Finnish subjects [32]
A54T -fatty acid composition
Japanese subjects without fasting hyperglycemia [14]
A54T + 2-hour post challenge insulin,
+ intraabdominal fat
Aboriginal Canadians [36]
A54T + plasma triglyceride
Finnish patients with familial combined hyperlipidemia [29]
A54T + lipid oxidation rate, HDL triglycerides,
+ LDL triglyceride
-insulin sensitivity
Obese Finnish subjects [33]
A54T -fasting insulin, glucose, lipid
-lipoprotein, basal metabolic rate,
-glucose and lipid oxidation
Japanese population [23]
A54T -insulin sensitivity
Japanese population [24]
A54T -dyslipidemia, hyperuricemia
-hyperinsulinemia
Guadeloupe Indian population [30]
A54T + triglyceride
American Caucasian population **
A54T + insulin sensitivity (%S)
E. Interventional study
Response to dietary fiber in Canadian subjects [36]
A54T + greater decreases in total
+ LDL cholesterol and Apo-B
Postprandial lipemic response in normotriglyceridemic subjects [35]
A54T + greater increases in chylomicron and VLDL triglycerides!
* "+" denotes positive association or linkage and "-" denotes negative association or linkage;  **the present study
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glucose) and %B = 20 x insulin / (glucose - 3.5). The
study was approved by the Institutional Review Board
and written informed consents were obtained at the en-
try of the study from each participant. We confirm that
the study has complied with the recommendations of the
Declaration of Helsinki.
Genotyping
Genomic DNA was extracted from peripheral leukocytes
using the method described previously [40]. A polymer-
ase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) assay was developed for genotyping.
The genomic DNA fragment flanking the A54T polymor-
phism was amplified using two primers flanking exon 2
of the FABP2 gene: CTACCGAGTTTTCTTCCCACC and
AATTAAACCATCCAATGAAATAGAGC. Polymerase
chain reaction (PCR) was carried out in an 11-µ l reaction
volume containing 0.5 pM of each primer, 0.2 mM
dNTP, 2 mM MgCl2, 5% glycerol, 0.275 U Taq polymer-
ase, 50 mM KC1, 10 mM Tris-HCl pH 8.3, and 0.1 µ g of
genomic DNA. The region of interest was amplified by an
initial denaturation at 94° C for 5 minutes, 35 cycles of
denaturation at 94° C for 30 seconds, annealing at 60° C
for 30 seconds, and extension at 72° C for 30 seconds,
and concluded with a final extension at 72° C for 10 min-
utes. Then, 5 µ l of the PCR product (375 base pairs) was
digested in a 15-µ l reaction volume containing 1 U of Hha
I (New England Biolabs Inc., Beverly, Massachusetts,
USA) with the buffer supplied by the vender. The digest-
ed PCR products were resolved on 2.0% agarose gels.
Hha I digested the wild type, Alanine (GCT), which yield-
ed two products, 200 and 175 base pairs (A allele). The G
to A substitution (Threonine, ACT) destroyed the Hha I
site (T allele).
Statistical analysis:
Variables, which failed the Normality test, were logarith-
mically transformed before analysis. They were age,
body mass index, waist-hip ratio, plasma insulin concen-
trations, %S, and %B. The relationship between the var-
iables and parameters of interest (%B or %S) was
determined by using univariate analysis. A multivariate
analysis using a stepwise-regression strategy was em-
ployed to examine the effect of covariates on the param-
eter of interest (%S and %B). The continuous covariates
were age, body mass index, waist-hip ratio, and systolic
and diastolic blood pressure. The categorical covariates
were gender and the FABP2 polymorphism. Backward
stepwise option with alpha-to-enter of 0.10 and alpha-
to-remove of 0.10 was employed to exclude covariates
that had much less or no influence on the parameter un-
der analysis, one at a time starting from the one had least
impact, which was based on the p value (the highest p
value). Stepwise regression analysis was stopped when
all the p values of all covariates, that were examined,
were less than 0.10. Since a very close linear relationship
was noted between systolic and diastolic pressure (r2 =
0.3586, p < 0.0001) and also between body mass index
and waist-hip ratio (r2 = 0.3014, p < 0.0001), they were
removed from the multivariate analysis based on their p
values as indicated in each analysis. A nominal P value of
less than 0.05 was considered significant. SYSTAT 8.0
for Windows from SPSS, Inc. (Chicago, Illinois) was used
for the statistical analysis.
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